NewsXbrane Biopharma releases 2016 Year End Report

Xbrane Biopharma ABs Year End Report for 2016 is now available on the Company’s website, www.xbrane.com.

October – December

  • Net sales 532 503 (83 736) SEK
  • Net sales growth 536 %
  • Total income 2 582 607 (599 747) SEK
  • Earnings before tax -10 099 892 (-5 331 005) SEK
  • Cash flow from current operations -12 262 437 (-8 980 850) SEK
  • Earnings per share -2,12 (-2,39) SEK

January – December

  • Net sales 2 490 117 (392 859) SEK
  • Net sales growth 534 %
  • Total income 4 689 201 (943 326) SEK
  • Earnings before tax -33 288 662 (-11 844 786) SEK
  • Cash flow from current operations -39 481 391 (-12 386 674) SEK
  • Earnings per share -7,00 (-5,18) SEK

Significant events during the fourth quarter

  • AIFA inspected the Spherotide production facility with positive results.
  • Xbrane received scientific advice regarding the regulatory and clinical strategy for Spherotide from the German Regulatory Authority, BfArM.
  • Xbrane signed a non-binding term-sheet with a Chinese pharmaceutical company regarding out-licensing of Spherotide in China.
  • Xbrane out-licensed the rights for sales and marketing of Spherotide to BioAvenir in Israel.
  • Xbrane appointed Anders P. Wiklund as a strategic advisor.

Significant events after the fourth quarter

  • Xbrane received GMP approval of Spherotide production facility in Italy from AIFA (Italian Medicines Agency).
  • Xbrane announced positive biosimilarity data on Xlucane.

For further information, please contact:
Martin Åmark, Chief Executive Officer Xbrane Biopharma
Tel: +46 (0) 763-093 777
E-mail: martin.amark@xbrane.com